CorMedix (NASDAQ:CRMD) Shares Gap Down Following Analyst Downgrade

CorMedix Inc (NASDAQ:CRMD) gapped down before the market opened on Thursday after Needham & Company LLC lowered their price target on the stock from $16.00 to $15.00. The stock had previously closed at $11.17, but opened at $8.73. Needham & Company LLC currently has a buy rating on the stock. CorMedix shares last traded at $8.0490, with a volume of 5,682,994 shares changing hands.

CRMD has been the topic of several other reports. Wall Street Zen downgraded shares of CorMedix from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. HC Wainwright lifted their price target on CorMedix from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Truist Financial set a $16.00 price target on shares of CorMedix in a research note on Thursday. Weiss Ratings reissued a “hold (c)” rating on shares of CorMedix in a research note on Wednesday, October 8th. Finally, D Boral Capital upgraded CorMedix from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $17.86.

Insider Buying and Selling

In other news, CEO Joseph Todisco sold 30,000 shares of the company’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $12.00, for a total transaction of $360,000.00. Following the completion of the sale, the chief executive officer directly owned 509,496 shares in the company, valued at $6,113,952. This represents a 5.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Alan W. Dunton sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $13.00, for a total value of $260,000.00. Following the completion of the transaction, the director owned 40,250 shares in the company, valued at approximately $523,250. This trade represents a 33.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 90,000 shares of company stock valued at $1,095,200 over the last three months. Insiders own 3.10% of the company’s stock.

Key Stories Impacting CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Analyst support remains: D. Boral Capital reaffirmed a “buy” rating with a $14 target, and Needham maintained a buy rating despite trimming its target from $16 to $15 — these endorsements help provide demand support for the shares. Analyst notes
• Positive Sentiment: Management continuity: CEO Joseph Todisco signed an extended employment contract and will add the Chairman role while the prior chair moves to Lead Independent Director — the move signals board-level continuity during the reset. Leadership update
• Neutral Sentiment: Investor outreach / visibility: Management will present a corporate overview at the J.P. Morgan Healthcare Conference (Jan 12), which could provide additional color and catalyze trading flows depending on guidance detail and Q&A. JPM presentation
• Neutral Sentiment: Valuation / bullish commentary: Coverage pieces (Zacks, Yahoo analysis) argue the stock may be undervalued or worth reassessing after the recent operational reset; these are watch items but not immediate catalysts. Zacks coverage
• Negative Sentiment: Material FY-2026 guidance reset: Management trimmed FY-2026 revenue guidance to $300–$320M versus consensus (~$445M), creating a large miss expectation and driving heavy selling pressure. Guidance cut article
• Negative Sentiment: Preliminary results and reduced outlook triggered downside: Q4/FY-2025 preliminary numbers were reported but the updated FY-2026 revenue range and related messaging prompted immediate negative investor reaction and headlines about a stock crash. Preliminary results
• Negative Sentiment: Reimbursement risk flagged: Analysis notes emerging CMS reimbursement headwinds that could pressure future revenue realization and margins — this is a structural risk that could sustain downward pressure if unresolved. CMS reimbursement analysis

Institutional Trading of CorMedix

Several large investors have recently modified their holdings of CRMD. SG Americas Securities LLC lifted its holdings in CorMedix by 38.6% in the fourth quarter. SG Americas Securities LLC now owns 28,182 shares of the company’s stock worth $328,000 after acquiring an additional 7,849 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of CorMedix by 35.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 302,508 shares of the company’s stock worth $3,518,000 after purchasing an additional 78,447 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of CorMedix by 6.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 27,540 shares of the company’s stock worth $310,000 after purchasing an additional 1,707 shares during the last quarter. Gryphon Financial Partners LLC acquired a new position in CorMedix during the 4th quarter valued at approximately $300,000. Finally, JPMorgan Chase & Co. grew its stake in CorMedix by 176.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 97,228 shares of the company’s stock worth $1,131,000 after buying an additional 62,085 shares during the last quarter. 34.18% of the stock is currently owned by institutional investors and hedge funds.

CorMedix Stock Up 1.6%

The company has a quick ratio of 1.73, a current ratio of 1.94 and a debt-to-equity ratio of 0.39. The firm’s 50 day simple moving average is $10.96 and its 200 day simple moving average is $11.62. The company has a market cap of $601.17 million, a price-to-earnings ratio of 3.70 and a beta of 1.36.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.78. CorMedix had a return on equity of 51.77% and a net margin of 75.83%.The business had revenue of $104.28 million during the quarter, compared to analysts’ expectations of $65.63 million. During the same period in the previous year, the firm earned ($0.05) earnings per share. The firm’s quarterly revenue was up 810.2% compared to the same quarter last year. Sell-side analysts anticipate that CorMedix Inc will post -0.32 EPS for the current fiscal year.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.